About the study

A Phase 2 Study of Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

1. Patients with metastatic or unresectable, recurrent head and neck squamous cell carcinoma (HNSCC) that is PD-L1 positive (CPS > 1) and who have not received prior systemic therapy for their advanced disease.
2. Adequate bone marrow function.
3. Adequate renal and liver function.
4. Adequate ECOG performance status.

Exclusion criteria

1. Patients with known symptomatic CNS metastases or leptomeningeal disease requiring steroids.
2. History of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
3. Prior treatment with any anti-CD47 or anti-SIRPα agent.
4. Prior treatment with anti-PD-1 or PD-L1.

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.